ReviewThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2023
Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination.
Review in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Co-infection of Hepatitis A and E With Atypical Manifestation: A Case Report.Clinical case reports · 2026Article
- From hepatitis A to acute liver failure in a resource-limited setting: a case report.IJID regions · 2026Article
- Single-Center Retrospective Study of Hospitalized Hepatitis A Cases in Southern Bulgaria, 2015-2023.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Review
- Evolving trends in hepatitis A epidemiology: Shifting patterns, emerging risks, and future strategies.World journal of virology · 2025Review
- Viral hepatitis as a differential diagnosis of yellow fever suspected cases in Cameroon: Prevalence and molecular characterization.IJID regions · 2025Article
- A Rare Case of Triple Infection with Leptospira, Hepatitis A Virus, and Hepatitis E Virus.Reports (MDPI) · 2025Article
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- Regional and age related variations in hepatitis A virus incidence in China 2004 to 2018: a descriptive epidemiological study.Scientific reports · 2025Article
- Redefining the immune landscape of hepatitis A virus infection.Experimental & molecular medicine · 2025Review
- Can Wastewater Surveillance Enhance Genomic Tracking of Climate-Driven Pathogens?Microorganisms · 2025Review
- Enhanced replication of a hepatitis A virus vaccine strain via adaptation in Vero cells.Clinical and experimental vaccine research · 2025Article
- Conservative Treatment of HAV-Associated Acalculous Acute Cholecystitis in an Adult: A Case Report.Case reports in medicine · 2025Article
- Prevalence of Soil-transmitted Helminth, Hepatitis A, andActa medica Philippina · 2025Article
- The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials.Current pharmaceutical biotechnology · 2025Review
- Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.Pharmaceutics · 2024Review
- Extracellular Vesicles in Viral Liver Diseases.Viruses · 2024Review
- Hijacking host extracellular vesicle machinery by hepatotropic viruses: current understandings and future prospects.Journal of biomedical science · 2024Review
- Oncoviral Infections and Small Extracellular Vesicles.Viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV) is one of the well-known viruses that cause hepatitis all around the globe. Although this illness has decreased in developed countries due to extensive immunization, numerous developing and under-developed countries are struggling with this virus. HAV infection can be spread by oral-fecal contact, and there are frequent epidemics through nutrition. Improvements in socioeconomic and sanitary circumstances have caused a shift in the disease's prevalence worldwide. Younger children are usually asymptomatic, but as they become older, the infection symptoms begin to appear. Symptoms range from slight inflammation and jaundice to acute liver failure in older individuals. While an acute infection may be self-limiting, unrecognized persistent infections, and the misapplication of therapeutic methods based on clinical guidelines are linked to a higher incidence of cirrhosis, hepatocellular carcinoma, and mortality. Fortunately, most patients recover within two months of infection, though 10-15% of patients will relapse within the first six months. A virus seldom leads to persistent infection or liver damage. The mainstay of therapy is based on supportive care. All children from 12-23 months, as well as some susceptible populations, should receive routine vaccinations, according to the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Laboratory diagnosis of HAV is based on antigen detection, checking liver enzyme levels, and antibody screening. Furthermore, polymerase chain reaction (PCR) technology has identified HAV in suspected nutrition sources; therefore, this technique is used for preventative measures and food-related laws.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.